Share Price and Basic Stock Data
Last Updated: March 6, 2026, 2:44 am
| PEG Ratio | 2.93 |
|---|
📊 Last updated
8d ago
Feb 26, 2026
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lincoln Pharmaceuticals Ltd operates within the pharmaceuticals industry and has shown a consistent growth trajectory in its revenue. For the fiscal year ending March 2025, the company reported sales of ₹623 Cr, marking an increase from ₹581 Cr in March 2024 and ₹510 Cr in March 2023. The quarterly sales figures also reflect an upward trend, with ₹156 Cr in September 2023 and ₹161 Cr projected for September 2024. The company’s operating profit margin (OPM) stood at 16% for the latest financial year, demonstrating stable profitability despite fluctuations in quarterly performance. Notably, the company has maintained a healthy revenue from operations per share of ₹311.15, underscoring its effective sales strategies and market positioning. This growth in revenue is supported by a robust operational framework and an increasing demand for pharmaceutical products, aligning well with the industry’s overall expansion.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | 1,248 Cr. | 623 | 679/440 | 14.2 | 357 | 0.29 % | 17.3 % | 12.8 % | 10.0 |
| TTK Healthcare Ltd | 1,216 Cr. | 861 | 1,402/856 | 17.5 | 768 | 1.16 % | 9.26 % | 6.89 % | 10.0 |
| Hester Biosciences Ltd | 1,284 Cr. | 1,509 | 2,350/1,243 | 31.4 | 397 | 0.46 % | 9.71 % | 9.18 % | 10.0 |
| Jagsonpal Pharmaceuticals Ltd | 1,139 Cr. | 170 | 302/155 | 26.7 | 37.9 | 1.47 % | 23.0 % | 18.6 % | 2.00 |
| Syncom Formulations (India) Ltd | 1,134 Cr. | 12.1 | 23.5/11.4 | 16.5 | 4.00 | 0.00 % | 18.6 % | 15.5 % | 1.00 |
| Industry Average | 20,550.65 Cr | 1,093.67 | 55.34 | 201.81 | 0.38% | 16.35% | 15.16% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 134 | 112 | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 |
| Expenses | 107 | 96 | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 |
| Operating Profit | 27 | 17 | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 |
| OPM % | 20% | 15% | 15% | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% | 16% | 14% |
| Other Income | 6 | 4 | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 31 | 17 | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 |
| Tax % | 29% | 26% | 25% | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% | 31% | 18% |
| Net Profit | 22 | 13 | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 |
| EPS in Rs | 10.79 | 6.27 | 9.49 | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 |
Last Updated: March 4, 2026, 1:46 am
Below is a detailed analysis of the quarterly data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 166.00 Cr.. The value appears strong and on an upward trend. It has increased from 163.00 Cr. (Sep 2025) to 166.00 Cr., marking an increase of 3.00 Cr..
- For Expenses, as of Dec 2025, the value is 143.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 138.00 Cr. (Sep 2025) to 143.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 25.00 Cr. (Sep 2025) to 24.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Dec 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Sep 2025) to 14.00%, marking a decrease of 2.00%.
- For Other Income, as of Dec 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Sep 2025) to 15.00 Cr., marking an increase of 8.00 Cr..
- For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 4.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Sep 2025) to 35.00 Cr., marking an increase of 6.00 Cr..
- For Tax %, as of Dec 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 31.00% (Sep 2025) to 18.00%, marking a decrease of 13.00%.
- For Net Profit, as of Dec 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Sep 2025) to 29.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 14.28. The value appears strong and on an upward trend. It has increased from 9.98 (Sep 2025) to 14.28, marking an increase of 4.30.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: February 24, 2026, 9:16 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 652 |
| Expenses | 190 | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 | 552 |
| Operating Profit | 20 | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 102 | 100 |
| OPM % | 10% | 10% | 10% | 13% | 15% | 18% | 17% | 21% | 20% | 18% | 17% | 16% | 15% |
| Other Income | 2 | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 | 31 |
| Interest | 7 | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Depreciation | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 | 14 |
| Profit before tax | 12 | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 | 115 |
| Tax % | 16% | 24% | 28% | 25% | 25% | 22% | 23% | 26% | 28% | 27% | 24% | 25% | |
| Net Profit | 10 | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 88 |
| EPS in Rs | 6.53 | 9.20 | 14.52 | 14.06 | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 | 43.86 |
| Dividend Payout % | 9% | 11% | 7% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% | 4% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | 60.00% | 16.67% | 25.00% | 40.00% | 4.08% | 21.57% | 11.29% | 5.80% | 27.40% | -11.83% |
| Change in YoY Net Profit Growth (%) | 0.00% | 10.00% | -43.33% | 8.33% | 15.00% | -35.92% | 17.49% | -10.28% | -5.49% | 21.60% | -39.23% |
Lincoln Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 10% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 25% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 15% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 9:50 am
Balance Sheet
Last Updated: January 7, 2026, 4:00 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 82 | 95 | 124 | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 | 696 |
| Borrowings | 68 | 76 | 78 | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | 0 | 0 |
| Other Liabilities | 93 | 70 | 56 | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 | 139 |
| Total Liabilities | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 855 |
| Fixed Assets | 65 | 66 | 98 | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | 185 |
| CWIP | 2 | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 | 3 |
| Investments | 0 | 0 | 0 | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 | 209 |
| Other Assets | 192 | 190 | 174 | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 | 458 |
| Total Assets | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 855 |
Below is a detailed analysis of the balance sheet data for Lincoln Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00 Cr..
- For Reserves, as of Sep 2025, the value is 696.00 Cr.. The value appears strong and on an upward trend. It has increased from 652.00 Cr. (Mar 2025) to 696.00 Cr., marking an increase of 44.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 139.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2025) to 139.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 855.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 797.00 Cr. (Mar 2025) to 855.00 Cr., marking an increase of 58.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 185.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2025) to 185.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 35.00 Cr..
- For Other Assets, as of Sep 2025, the value is 458.00 Cr.. The value appears strong and on an upward trend. It has increased from 437.00 Cr. (Mar 2025) to 458.00 Cr., marking an increase of 21.00 Cr..
- For Total Assets, as of Sep 2025, the value is 855.00 Cr.. The value appears strong and on an upward trend. It has increased from 797.00 Cr. (Mar 2025) to 855.00 Cr., marking an increase of 58.00 Cr..
Notably, the Reserves (696.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -50.00 | -37.00 | -17.00 | -8.00 | 34.00 | 61.00 | 86.00 | 94.00 | 88.00 | 99.00 | 102.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 154 | 163 | 73 | 92 | 111 | 122 | 96 | 98 | 90 | 98 | 102 | 97 |
| Inventory Days | 62 | 44 | 36 | 63 | 86 | 75 | 95 | 86 | 121 | 106 | 101 | 99 |
| Days Payable | 174 | 92 | 40 | 54 | 82 | 92 | 102 | 105 | 120 | 77 | 95 | 106 |
| Cash Conversion Cycle | 43 | 116 | 70 | 100 | 115 | 106 | 88 | 78 | 91 | 126 | 108 | 90 |
| Working Capital Days | 13 | 76 | 31 | 69 | 89 | 113 | 126 | 119 | 113 | 121 | 127 | 217 |
| ROCE % | 11% | 15% | 21% | 19% | 19% | 23% | 22% | 25% | 24% | 22% | 22% | 18% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 106 | 0.08 | 0.01 | 106 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| Diluted EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| Cash EPS (Rs.) | 47.55 | 51.89 | 40.97 | 38.66 | 34.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 187.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 187.85 |
| Revenue From Operations / Share (Rs.) | 311.15 | 289.84 | 254.78 | 235.71 | 212.09 |
| PBDIT / Share (Rs.) | 61.89 | 67.07 | 55.76 | 52.66 | 46.42 |
| PBIT / Share (Rs.) | 55.45 | 61.76 | 51.18 | 48.62 | 42.64 |
| PBT / Share (Rs.) | 54.51 | 61.03 | 50.16 | 47.90 | 41.86 |
| Net Profit / Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.12 |
| NP After MI And SOA / Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 31.11 |
| PBDIT Margin (%) | 19.89 | 23.13 | 21.88 | 22.34 | 21.88 |
| PBIT Margin (%) | 17.82 | 21.30 | 20.08 | 20.62 | 20.10 |
| PBT Margin (%) | 17.51 | 21.05 | 19.68 | 20.32 | 19.73 |
| Net Profit Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.67 |
| NP After MI And SOA Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.66 |
| Return on Networth / Equity (%) | 12.25 | 15.73 | 14.50 | 16.02 | 16.58 |
| Return on Capital Employeed (%) | 16.07 | 20.34 | 19.89 | 21.94 | 22.10 |
| Return On Assets (%) | 10.33 | 13.32 | 12.41 | 12.97 | 13.54 |
| Asset Turnover Ratio (%) | 0.83 | 0.90 | 0.90 | 0.95 | 0.99 |
| Current Ratio (X) | 4.71 | 4.84 | 5.08 | 3.90 | 4.17 |
| Quick Ratio (X) | 3.97 | 4.00 | 4.11 | 3.10 | 3.53 |
| Inventory Turnover Ratio (X) | 8.00 | 7.89 | 2.48 | 2.66 | 2.18 |
| Dividend Payout Ratio (NP) (%) | 4.37 | 3.22 | 4.12 | 4.32 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.78 | 2.89 | 3.66 | 3.87 | 0.00 |
| Earning Retention Ratio (%) | 95.63 | 96.78 | 95.88 | 95.68 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.22 | 97.11 | 96.34 | 96.13 | 0.00 |
| Interest Coverage Ratio (X) | 65.84 | 91.70 | 55.01 | 72.68 | 59.44 |
| Interest Coverage Ratio (Post Tax) (X) | 44.74 | 64.69 | 36.91 | 48.79 | 40.86 |
| Enterprise Value (Cr.) | 1082.31 | 1159.77 | 646.08 | 574.49 | 436.11 |
| EV / Net Operating Revenue (X) | 1.74 | 2.00 | 1.27 | 1.22 | 1.03 |
| EV / EBITDA (X) | 8.73 | 8.63 | 5.79 | 5.45 | 4.70 |
| MarketCap / Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| Retention Ratios (%) | 95.62 | 96.77 | 95.87 | 95.67 | 0.00 |
| Price / BV (X) | 1.64 | 1.98 | 1.35 | 1.44 | 1.20 |
| Price / Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| EarningsYield | 0.07 | 0.07 | 0.10 | 0.11 | 0.13 |
After reviewing the key financial ratios for Lincoln Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For Diluted EPS (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For Cash EPS (Rs.), as of Mar 25, the value is 47.55. This value is within the healthy range. It has decreased from 51.89 (Mar 24) to 47.55, marking a decrease of 4.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 335.34. It has increased from 295.98 (Mar 24) to 335.34, marking an increase of 39.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 335.34. It has increased from 295.98 (Mar 24) to 335.34, marking an increase of 39.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 311.15. It has increased from 289.84 (Mar 24) to 311.15, marking an increase of 21.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.89. This value is within the healthy range. It has decreased from 67.07 (Mar 24) to 61.89, marking a decrease of 5.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 55.45. This value is within the healthy range. It has decreased from 61.76 (Mar 24) to 55.45, marking a decrease of 6.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 54.51. This value is within the healthy range. It has decreased from 61.03 (Mar 24) to 54.51, marking a decrease of 6.52.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 41.11. This value is within the healthy range. It has decreased from 46.58 (Mar 24) to 41.11, marking a decrease of 5.47.
- For PBDIT Margin (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has decreased from 23.13 (Mar 24) to 19.89, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 17.82. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 17.82, marking a decrease of 3.48.
- For PBT Margin (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 21.05 (Mar 24) to 17.51, marking a decrease of 3.54.
- For Net Profit Margin (%), as of Mar 25, the value is 13.21. This value exceeds the healthy maximum of 10. It has decreased from 16.07 (Mar 24) to 13.21, marking a decrease of 2.86.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. It has decreased from 16.07 (Mar 24) to 13.21, marking a decrease of 2.86.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.25. This value is below the healthy minimum of 15. It has decreased from 15.73 (Mar 24) to 12.25, marking a decrease of 3.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 20.34 (Mar 24) to 16.07, marking a decrease of 4.27.
- For Return On Assets (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 13.32 (Mar 24) to 10.33, marking a decrease of 2.99.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has decreased from 0.90 (Mar 24) to 0.83, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.71. This value exceeds the healthy maximum of 3. It has decreased from 4.84 (Mar 24) to 4.71, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 2. It has decreased from 4.00 (Mar 24) to 3.97, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 7.89 (Mar 24) to 8.00, marking an increase of 0.11.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.37. This value is below the healthy minimum of 20. It has increased from 3.22 (Mar 24) to 4.37, marking an increase of 1.15.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.78. This value is below the healthy minimum of 20. It has increased from 2.89 (Mar 24) to 3.78, marking an increase of 0.89.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.63. This value exceeds the healthy maximum of 70. It has decreased from 96.78 (Mar 24) to 95.63, marking a decrease of 1.15.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.22. This value exceeds the healthy maximum of 70. It has decreased from 97.11 (Mar 24) to 96.22, marking a decrease of 0.89.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 65.84. This value is within the healthy range. It has decreased from 91.70 (Mar 24) to 65.84, marking a decrease of 25.86.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 44.74. This value is within the healthy range. It has decreased from 64.69 (Mar 24) to 44.74, marking a decrease of 19.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,082.31. It has decreased from 1,159.77 (Mar 24) to 1,082.31, marking a decrease of 77.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.74, marking a decrease of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 8.73. This value is within the healthy range. It has increased from 8.63 (Mar 24) to 8.73, marking an increase of 0.10.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.77, marking a decrease of 0.25.
- For Retention Ratios (%), as of Mar 25, the value is 95.62. This value exceeds the healthy maximum of 70. It has decreased from 96.77 (Mar 24) to 95.62, marking a decrease of 1.15.
- For Price / BV (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.98 (Mar 24) to 1.64, marking a decrease of 0.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.77, marking a decrease of 0.25.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lincoln Pharmaceuticals Ltd:
- Net Profit Margin: 13.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.07% (Industry Average ROCE: 16.35%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.25% (Industry Average ROE: 15.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 44.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.97
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.2 (Industry average Stock P/E: 55.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.21%
About the Company - Qualitative Analysis
Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 623.23 Cr. and Equity Capital is Rs. 20.03 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Lincoln House, Ahmedabad Gujarat 380060 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kishor M Shah | Non Executive Chairman |
| Mr. Mahendra G Patel | Managing Director |
| Mr. Hashmukh I Patel | Whole Time Director |
| Mr. Munjal M Patel | Whole Time Director |
| Mr. Ashish R Patel | Whole Time Director |
| Mr. Rajnikant G Patel | Non Executive Director |
| Mr. Nareshkumar Suthar | Independent Director |
| Mr. Saurin J Parikh | Independent Director |
| Ms. Seema Mehta | Independent Director |
FAQ
What is the intrinsic value of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd's intrinsic value (as of 06 March 2026) is ₹545.80 which is 12.39% lower the current market price of ₹623.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,248 Cr. market cap, FY2025-2026 high/low of ₹679/440, reserves of ₹696 Cr, and liabilities of ₹855 Cr.
What is the Market Cap of Lincoln Pharmaceuticals Ltd?
The Market Cap of Lincoln Pharmaceuticals Ltd is 1,248 Cr..
What is the current Stock Price of Lincoln Pharmaceuticals Ltd as on 06 March 2026?
The current stock price of Lincoln Pharmaceuticals Ltd as on 06 March 2026 is ₹623.
What is the High / Low of Lincoln Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lincoln Pharmaceuticals Ltd stocks is ₹679/440.
What is the Stock P/E of Lincoln Pharmaceuticals Ltd?
The Stock P/E of Lincoln Pharmaceuticals Ltd is 14.2.
What is the Book Value of Lincoln Pharmaceuticals Ltd?
The Book Value of Lincoln Pharmaceuticals Ltd is 357.
What is the Dividend Yield of Lincoln Pharmaceuticals Ltd?
The Dividend Yield of Lincoln Pharmaceuticals Ltd is 0.29 %.
What is the ROCE of Lincoln Pharmaceuticals Ltd?
The ROCE of Lincoln Pharmaceuticals Ltd is 17.3 %.
What is the ROE of Lincoln Pharmaceuticals Ltd?
The ROE of Lincoln Pharmaceuticals Ltd is 12.8 %.
What is the Face Value of Lincoln Pharmaceuticals Ltd?
The Face Value of Lincoln Pharmaceuticals Ltd is 10.0.